Identification of C3 beta chain as the human serum eosinophil cytotoxicity inhibitor by unknown
Brief Det~nitlve  Report 
Identification  of C3/3  Chain  as the Human  Serum 
Eosinophil Cytotoxicity Inhibitor 
By Marjorie S. Minkoff, Winnie W. Wong, 
and David S. Silberstein 
From the Department of Rkeumatology and Immunology, Brigham and Women's Hospital, and 
the Department of Medicine, Harvard Medical School, Boston, Massachusetts 02115 
Summary 
An eosinophil cytotoxicity inhibitor (ECI) was purified from serum of a human subject with 
severe allergic dermatitis. Molecular weight of the isolated polypeptide (75,000)  and its NHz- 
terminal amino acid sequence  identified it as the 13 chain of the C3 complement component 
(apparently free, but perhaps attached to very small fragments of the c~ chain). Free/3 chain, 
prepared from normal plasma by reduction of C3, inhibited both eosinophil cytotoxicity and 
neutrophil adherence functions, with half-maximal activity at "~250 ng/ml. Apparently free C3 
13 chain was detected in certain human biological fluids associated with inflammation; the presence 
of C3/3 chain correlated with ECI activity. This evidence demonstrates a potential role for free 
C3/3 chain as a suppressor  of eosinophil and neutrophil functions in inflammation. 
S 
erum from a small percentage of recently studied human 
subjects, including three with chronic inflammation, con- 
tained a "~80-kD polypeptide (eosinophil cytotoxicity  inhib- 
itor [ECI]) that suppressed  the cytotoxic function of TNF- 
or granulocyte/macrophage  (GM)-CSF-stimulated eosinophils. 
Normal human serum contained an inactive precursor of  ECI 
that could be activated artificially by certain chromatographic 
procedures.  It was hypothesized that, in vivo,  ECI is acti- 
vated by some property of inflammation (1). 
Here we describe  the purification of ECI from serum of 
a human subject with severe allergic  dermatitis. We show 
that this substance is structurally similar and probably iden- 
tical to the/3 chain of the C3 complement component, that 
free/~ chain prepared from normal plasma has the activity 
of ECI, and that apparently free C3/3 chain exists in certain 
human biological fluids  associated  with inflammation. 
Materials and Methods 
Isolation of  ECI.  The following protocol was developed, based 
on the screening of  fractions with eosinophil cytotoxicity and ueu- 
trophil adherence assays (see below). Fractions containing the in- 
hibitor did not affect eosinophil or neutrophil viability, as judged 
by trypan blue exclusion  and HzO2 release after PMA stimulus (1). 
Serum from a human subject with severe allergic dermatitis was 
brought to 50% saturation with ammonium sulfate at 0~  over- 
night and centrifuged at 12,000 g. The supernatant portion was 
brought to 65% saturation, reincubated, and centrifuged as above. 
The resulting pallet was dissolved  and dialyzed in 0.04 M sodium 
phosphate buffer, pH 7.2, and then incubated with controlled pore 
glass beads (1:100 [vol/vol]; Electronucleonics,  Fairfield, NJ). The 
beads were washed with 20% and then 30% ethylene glycol in 
the same buffer. Material from the 30% wash was subjected to 
dialysis (H20), lyophilization, and applied to a TSK-Phenyl  5PW 
7.5  x  75-ram column (HPLC). Bound proteins were eluted with 
a 45-rain gradient of 0.6 M ammonium sulfate in 100 mM phos- 
phate, pH 7.0., to 30% ethylene glycol in 10 mM phosphate, pH 
7.0. The material collected from 28-31 rain of the gradient was 
dialyzed  in 0.02 M Tris, pH 7.0, and applied to a TSK-DEAE 5PW 
7.5  x  75-mm  column. Bound material was eluted with a 45-min 
gradient to 0.5 M ammonium sulfate in the same buffer. The ma- 
terial collected from 10-13 rain of this gradient was collected and 
applied to a Vydac  C-4 4.6 x 250-mm column, washed with 0.1% 
trifluoroacetic acid, and eluted with a 30-min gradient to 50% 
acetonitrile in 0.1% trifluoroacetic acid. The active material was 
recovered at 19 or 20 rain of this gradient. 
Biological Assays.  Human eosinophils, isolated at 80-99% pu- 
rity (2), were tested for the ability to kill larvae ofSchistosoma man- 
soni in the presence of antibody (3) and a test or control source 
of inhibitor. The eosinophils were treated with either 100 U/ml 
of purified recombinant TNF (Cetus Corp., Emeryville, CA) or 
20 pM purified recombinant GM-CSF (Dr. Judith C.  Gasson, 
UCLA School of Medicine) in order to activate the killing func- 
tions (4, 5). 
Neutrophils were isolated at >95% purity by dextran sedimen- 
tation, centrifugation through a cushion of Ficoll-Hypaque (Phar- 
macia Fine Chemicals, Piscataway, NJ), and hypotonic lysis to re- 
move remaining  erythrocytes.  For assay  of  adherence to tissue  culture 
plastic, 10  s neutrophils were added to tissue culture plate micro- 
wells (Falcon  Labware,  Oxnard, CA) in 200 #1 of  medium (RPMI, 
pH  7.2; 100 U/ml penicillin G;  100 #g/ml streptomycin; 8% 
NuSerum [Collaborative  Research, Waltham, MA]; and 2% HIFCS) 
containing 100 U/ml recombinant  TNF and a test or control source 
of inhibitor. The neutrophils were allowed to adhere at 37~  for 
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warm saline. The wells were emptied of liquid and filled with 200 
#1 of a solution containing 0.1% Triton X-100, 0.4 mM 2-2' azino- 
di-3-ethyl-benzthiazoline-6-sulfonate plus 0.003% hydrogen per- 
oxide in 0.05 M sodium citrate, pH 4.0. The generation of colored 
product (absorbance monitored at 405 nm) reflected the quantity 
of cell-derived myeloperoxidase in the wells and correlated with 
visual assessments of cell adherence. 
Amino Acid Sequence  Analysis.  After tentative identification as 
ECI, the 75-kD polypeptide species was isolated in quantities suit- 
able for amino acid sequence analysis after size exclusion HPLC 
of allergic dermatitis serum. The fraction containing ECI activity 
was separated by SDS-PAGE (10% polyacrylamide  under reducing 
conditions). Polypeptide species were then transferred to FVDF 
membrane and stained with coomassie blue. Material from SDS- 
PAGE run in parallel was recovered by electroelution of gel slices. 
These samples were dialyzed in medium and tested for the ability 
to inhibit eosinophil  cytotoxic function. The region of PVDF mem- 
brane containing the polypeptide species that was associated with 
inhibitory activity was then excised and submitted for amino acid 
sequence analysis (performed by Margaret Ehrhardt, Brigham and 
Womeffs Hospital core sequencing facility, using a Gas Phase Pro- 
tein Sequencer [475A; Applied Biosystems,  Inc., Foster City, CA]). 
Computer search was carried out for a translated version of Gen- 
Bank data base 61. 
Preparation of C3 Fragments.  C3 was prepared from normal 
human plasma according to reference 6. For separation of the/3 
chain, C3 was reduced in 10% 2-ME for 1 h at room temperature. 
To alkylate sulflaydryl  groups, portions of the reduced material were 
mixed with an equal volume of 0.75 M iodoacetamide on ice for 
1 h. Free/3 chain was isolated by preparative SDS-PAGE under 
reducing conditions and electroelution in 0.05 M ammonium bi- 
carbonate. Ehted protein and similarly  processed  material from other 
regions of the gels (control samples) were dialyzed in medium. C3c 
was prepared by trypsin digestion of C3 (7) and analyzed by SDS- 
PAGE. Protein concentrations were determined by the Bradford 
method (reagents from Pierce Chemical Co., Rockford, IL). 
Detection of C3 ~ Chain by Western Blot Analysis.  1-/~1  samples 
of biological fluids were separated  by SDS-PAGE (nonreducing con- 
ditions)/Western blot analysis (8), using a peroxidase-conjugated 
second antibody (anti-mouse IgG, A,M; diluted 1/10,000; Cappel 
Laboratories, Malvern, PA). After electrophoretic transfer to PVDF 
membrane, the resolved species were detected by treatment with 
pooled culture supernatants from four ~ chain-specific hybridoma 
lines. 
The bybridomas were generated after immunization of BALB/c 
mice with "~100/zg of purified C313 chain in CFA and subsequently 
IFA. Spleen cells were fused with SP2 myeloma cells and cultured 
in selective medium according to standard methods. Hybridoma 
culture supernatants were screened  by ELISA  and Western blot anal- 
),sis for reactivity with free C3 13 chain in reduced preparations 
of purified C3.  Positive hybridoma lines were subcloned twice. 
Results and Discussion 
ECI was purified from serum of a human subject with se- 
vere allergic dermatitis by a sequence of methods including: 
high salt precipitation, controlled pore glass bead chroma- 
tography, hydrophobic interaction HPLC,  anion exchange 
HPLC, and reversed-phase HPLC. Two biological assays, in- 
hibition of human eosinophil cytotoxic function and of human 
neutrophil adherence to tissue culture plastic,  were used to 
evaluate samples generated by chromatography. These methods 
allowed the tentative identification of ECI as a 75-kD species 
(Fig.  1). During all steps of the purification, there was ap- 
proximate  agreement  between  the  eosinophil-based  and 
neutrophil-based assays, suggesting that the inhibitory ac- 
tivity affects both leukocyte types. 
A partial NH2-terminal amino acid sequence for purified 
ECI is shown below. Computer search of known polypep- 
tide sequences revealed  strong homology of ECI to the B 
chain of the C3 complement component (sequences aligned 
below). 
Purified ECI:  ? -Pro-Met-Tyr-Ser-Ile- ? -Thr-Pro-Asn- 
C3/3  chain:  Ser-Pro-Met-Tyr-Ser-Ile-Ile-Thr-Pro-Asn- 
?-  ?  ?  -Leu-Glu-Ser-  ?  -Glu-  ?  -Met .... 
Ile - Leu - Ala -Leu-Glu-Ser- Glu -Glu- Thr -Met  .... 
The apparent molecular mass of ECI (75 kD) was also in 
agreement with the known mass of the C3/3 chain. This 
suggests that ECI is free/3 chain, but does not rule out the 
possibility that it is attached to very small fragments of the 
ol chain. 
To test the relationship between ECI and C3/3 chain by 
an alternative method, we studied activity of the following 
substances,  all  purified  from  normal  human  plasma  (see 
Materials and Methods): C3, C3 treated with 2-ME to sepa- 
rate the ol and/3 chains, C3 reduced and alkylated with io- 
doacetamide to prevent possible reassociation of the c~ and 
/3 chains, and free/3 chain. 
Intact C3 had no significant inhibitory activity at concen- 
trations as high as 120/~g/ml of protein. Reduction of C3, 
and particularly reduction and alkylation, to generate free 
/3 chain produced substantial inhibitory activity. Free/3 chain 
exhibited the greatest activity (half maximal at ~250 ng/ml), 
though a mock preparation from an adjacent SDS-PAGE slice 
had negligible activity. Alkylation did not affect the activity 
of free/3 chain, demonstrating the absence of a functional 
role for the reduced sulfhydryl groups (Fig.  2). 
As C3c (C3/3 chain attached to 43- and 27-kD fragments 
of the o~ chain by disulfide bonds) is generally considered the 
terminal cleavage product of C3 during the activation of com- 
plement (10,  11), we wanted to learn whether C3c had in- 
hibitory activity similar to free/3 chain. C3c was prepared 
by trypsin digestion of C3 and tested in assays of eosinophil 
cytotoxic function and neutrophil adherence. This material 
exhibited no detectable inhibitory activity (data not shown). 
Several clinically interesting biological fluids were tested 
for the presence of C3/3 chain by Western blot analysis of 
SDS-PAGE  gels (nonreducing conditions). Apparently free 
/3 chain was detected in plasma drawn from a human subject 
during a severe allergic dermatitis reaction and in synovial 
fluid of two patients with rheumatoid arthritis (one example 
shown), but not in normal plasma (Fig. 3 A). The presence 
of free/3 chain correlated with the ability of these biological 
fluids to inhibit eosinophil cytotoxic function (comparison 
of Fig.  3, A  and B). 
Control experiments indicated that levels of/3 chain in 
samples were not affected substantially by the process of coagu- 
1268  3 Chain as the Human Serum Eosinophil Cytotoxicity  Inhibitor Figure  1.  Tentative identification of ECI as a 75-kD peptide. (A) An example of the anion exchange HPLC step. The elution gradient and profile 
of eluted polypeptides are indicated. The inset shows  the SDS-PAGE analysis of the fractions assayed for activity in B, with purified ECI and (for 
comparison) human serum albumin indicated. (B) Effect of chromatography fractions on eosinophil cytotoxic function. The data represent means (plus 
SE) from five experiments with eosinophils  obtained from different  donors. The 100%  value represents  cytokine-stimulated (in this case, 100 U/ml 
of TNF, however, similar results were obtained with 20 pM GM-CSF) eosinophil cytotoxic function or neutrophil adherence. The 0% value represents 
the low or negligible functions (which were subtracted as background) in the absence of cytokine stimulation. Note the presence of the 75-kD polypep- 
tide in fractions (primarily fractions 27 and 28) with inhibitory activity. 
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Figure  2.  Inhibition of eosinophil and neutrophil function by free C3/5 chain. C3 (~), reduced C3 (A), reduced and alkylated C3 (&), reduced 
([-]), or reduced and alkylated (I)/5 chain recovered by electroelution from SDS-PAGE, and a mock preparation electroeluted  from a reducing SDS-PAGE 
gel (O) were tested  for inhibition of eosinophil cytotoxic function (A) and neutrophil adherence  (B). 
lation or the choice of anticoagulant method. Furthermore, 
activation  of complement by zymosan treatment  did not 
generate  ~  chain or its inhibitory activity,  as evaluated by 
Western blot analysis and bioassays (data not shown). To this 
point, our work does not provide indications regarding the 
molecular  mechanisms  or  specific disease processes that 
generate  the/3 chain inhibitory substance. 
The stepwise cleavage of C3 to C3c during the activation 
of complement generates C3a, C3b, C3bi, and C3dg, which 
all enhance leukocyte functions in the development ofinflam- 
mation (10-14). For example, C3b or C3bi enhance eosino- 
phil functions, including cytotoxicity (12, 13), and promote 
neutrophil functions, including adherence (10-14). Here, we 
present evidence that C3 ~ chain inhibits these functions and 
that apparently free B chain exists as a discreet entity in bio- 
logical fluids associated with inflammation. Taken  collectively, 
this evidence demonstrates  a potential role of C3/~ chain as 
a  feedback mechanism to  suppress leukocyte  functions in 
inflammation. 
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chain in  selected human biological 
fluids. Normal  plasma  (O), plasma  from 
an allergic  dermatitis  patient (A), and 
synovial fluid from a rheumatoid ar- 
thritis patient (I) were analyzed.  (A) 
Western blot analysis indicating the 
presence of/5  chain  in various  C3 forms 
(C3 spp.) in all samples  and free/5  chain 
only  in ADP and RASF. (B) Inhibitory 
activity  of these biological  fluids  with 
respect to eosinophil  cytotoxic  function. 
Note that inhibition  correlated  with the 
presence of free/5 chain. 
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